Literature-reported formulation composition
Component: AO12 | Reported molar ratio: 2.44 | Role: Ionizable lipid
sales@dcchemicals.com
Antioxidant lipid AO12
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: SM-102 | Reported molar ratio: 48.78 | Role: Ionizable lipid
Literature-reported formulation composition
Component: DSPC | Reported molar ratio: 9.76 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Cholesterol | Reported molar ratio: 37.56 | Role: Sterol
Literature-reported formulation composition
Component: DMG-PEG2000 | Reported molar ratio: 1.46 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported ratio sum | Reported molar ratio: 100 | Role: Original ratio retained
Reported observation
Literature-reported Antioxidant score 89% for AO12LNPs versus 57% for cLNPs 0.05 mM reactive-species panel; AO12 at 5 mol% relative to SM-102 · Supplementary Table 2 / Fig. 2e-f · Commercial SM-102 LNPs Main article p. 4, Fig. 2e-f; Supplementary Information p. 76, Supplementary Table 2.
Reported observation
Literature-reported Full-length FLuc mRNA after oxidative challenge 58% versus 41% after ·OH; 47% versus 25% after ONOO− Extracted FLuc mRNA from AO12LNPs versus cLNPs · After 2 h reactive-species exposure; capillary electrophoresis · cLNPs Main article p. 5, Fig. 3e.
Reported observation
Literature-reported Reporter-expression retention under PMA oxidative stress 85–87% versus 53–59% for corresponding control formulations AO12 incorporated at 5 mol% into MC3- and ALC-0315-based LNPs · PMA-induced oxidative stress; luciferase readout · Corresponding MC3 or ALC-0315 controls Main article p. 5; Supplementary Figs. 60-61.
Reported observation
Literature-reported Acute liver injury linear FLuc mRNA AO12LNPs preserved approximately 89% of healthy-liver expression versus approximately 33% for cLNPs APAP-induced acute liver injury; i.v. FLuc mRNA · 6 h post-injection · cLNPs Main article p. 8, Fig. 4b-c; Supplementary Fig. 83.
Reported observation
Literature-reported Acute liver injury circRNA AO12LNPs preserved 70% versus 29% for cLNPs APAP-induced acute liver injury; i.v. FLuc circRNA · 6 h post-injection · cLNPs Main article p. 8, Fig. 4d-e; Supplementary Fig. 83.
Reported observation
Literature-reported Lung injury linear FLuc mRNA 77% versus 49% of healthy-lung expression LPS-induced acute lung injury with lung-targeting DOTAP-containing LNPs · 6 h post-injection · lung-cLNPs Main article p. 8, Fig. 4f-h; Supplementary Fig. 84.
Reported observation
Literature-reported Lung fibrosis linear FLuc mRNA 45% versus 19% of healthy-lung expression Bleomycin-induced pulmonary fibrosis with lung-targeting LNPs · 6 h post-injection · lung-cLNPs Main article p. 8, Fig. 4f-h; Supplementary Fig. 85.
Reported observation
Literature-reported HGF expression in chronic liver fibrosis 2.8-fold versus fibrosis group and 1.3-fold versus cLNPs CCl4-induced liver fibrosis; HGF mRNA AO12LNPs · After three injections at 4-day intervals · Fibrosis group and HGF-mRNA cLNPs Main article p. 9, Fig. 5g-h; Supplementary Fig. 88.
Reported observation
Literature-reported Liver injury markers in chronic fibrosis AST reduced 44% and ALT 92% versus fibrosis group; cLNPs reduced AST 26% and ALT 31% HGF mRNA treatment · Two days after final injection · Fibrosis group and cLNPs Main article p. 9, Fig. 5i-l.
Reported observation
Literature-reported NLRP3 on-target editing 23.67% indel frequency RAW264.7 macrophages treated with AO12LNPs carrying Cas9 mRNA and NLRP3 sgRNA · 72 h after treatment · The study reports no measurable editing at five predicted off-target loci Main article p. 13; Supplementary Fig. 110 and Supplementary Tables 6-7.
Reported observation
AO12 identity and analytical characterization AO12 is the para-hydroxyphenylpropionic-acid derivative in the phenol-derived AO12–16 series. Compound characterization · Supplementary Information p. 4, Compound AO12; Supplementary Fig. 24.
Reported observation
High-speed microfluidic preparation Three independent AO12LNP batches were made using a Micro&Nano microfluidic chip at a reported flow rate of 200 mL/min; the batches retained comparable particle properties and expression in the cited study. Process demonstration · Main article p. 5; Supplementary Fig. 62.
Reported observation
Safety observations in the cited models Cell viability remained above 88% at 10 µg/mL in the reported cytotoxicity experiment; hemolysis and healthy-mouse body weight, histology, ALT/AST and inflammatory cytokines were reported as comparable to controls under the tested conditions. These are study-specific observations, not a general safety conclusion. Safety-related assays · Main article p. 6; Supplementary Figs. 66-73.